- Home
- GYRE vs TXO Comparison
GYRE vs TXO Comparison
Compare GYRE & TXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- TXO
- Stock Information
- Founded
- GYRE 2002
- TXO 2012
- Country
- GYRE United States
- TXO United States
- Employees
- GYRE N/A
- TXO N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- TXO Oil & Gas Production
- Sector
- GYRE Health Care
- TXO Energy
- Exchange
- GYRE Nasdaq
- TXO Nasdaq
- Market Cap
- GYRE 755.7M
- TXO 701.2M
- IPO Year
- GYRE N/A
- TXO 2023
- Fundamental
- Price
- GYRE $8.19
- TXO $13.74
- Analyst Decision
- GYRE Strong Buy
- TXO Strong Buy
- Analyst Count
- GYRE 2
- TXO 2
- Target Price
- GYRE $17.00
- TXO $20.50
- AVG Volume (30 Days)
- GYRE 60.0K
- TXO 159.7K
- Earning Date
- GYRE 11-07-2025
- TXO 11-04-2025
- Dividend Yield
- GYRE N/A
- TXO 17.50%
- EPS Growth
- GYRE N/A
- TXO N/A
- EPS
- GYRE 0.04
- TXO 0.36
- Revenue
- GYRE $107,265,000.00
- TXO $364,412,000.00
- Revenue This Year
- GYRE $15.25
- TXO $32.13
- Revenue Next Year
- GYRE $33.14
- TXO $11.48
- P/E Ratio
- GYRE $211.54
- TXO $38.28
- Revenue Growth
- GYRE 2.13
- TXO 27.66
- 52 Week Low
- GYRE $6.11
- TXO $12.61
- 52 Week High
- GYRE $19.00
- TXO $20.70
- Technical
- Relative Strength Index (RSI)
- GYRE 59.01
- TXO 60.76
- Support Level
- GYRE $7.12
- TXO $13.01
- Resistance Level
- GYRE $7.42
- TXO $13.97
- Average True Range (ATR)
- GYRE 0.34
- TXO 0.30
- MACD
- GYRE 0.04
- TXO 0.11
- Stochastic Oscillator
- GYRE 94.82
- TXO 85.63
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.